Dear Colleague,

Fortis Clinical Research Ltd (FCRL) was established over two years ago as a professional CRO offering quality clinical research services in India. During this period, FCRL has come a long way. It has been audited and approved by the Drugs Controller General of India and by several leading Indian and International pharmaceutical companies. Pivotal bioequivalence studies have been conducted for several international regulatory bodies and we already have approval from ANVISA, the Brazilian agency.

With a successful financial year behind us, FCRL is now expanding its facilities and services. We will be providing enhanced infrastructure for the evaluation of generic products by way of adding more beds and LC/MS/MS machines so that BE study slots may be available on demand to sponsors. We will now also offer clinical trial services including first-in-man phase I studies, proof-of-concept phase II studies and phase III trials in oncology, cardiovascular and metabolic diseases. Data management, medical writing and pharmacovigilance services will also be provided.

With the availability of our augmented infrastructure, FCRL will continue to provide enhanced capacity and flexibility with international quality you expect of us. All this, and more, at our usual cost-effective prices. Should you have any specific query for your project, please do not hesitate to contact me at satish.bhatia@fortis-cro.com

With best regards,

Sincerely,
Satish Bhatia, PhD